Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT01208090 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT01208090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01208090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
Lead sponsor
Actelion
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
November 30, 2012
Enrollment
326 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis